Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4007 Pharmacy

Closed 09-09 16:00:00 EDT

960.37

-4.76

-0.49%

High971.02	Low959.75	Vol241.17M
Open965.02	D1 Closing965.13	Amplitude1.17%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O11.18B	T/O Rate--	Tradable Shares0.00
P/B5.674533	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4007","market":"US","secType":"PLATE","nameCN":"Pharmacy","latestPrice":960.3723,"timestamp":1788983999999,"preClose":965.1294,"halted":0,"volume":241167825,"delay":0,"changeRate":-0.004929,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-4.75708,"latestTime":"09-09 16:00:00 EDT","open":965.0197,"high":971.01917,"low":959.75336,"amount":11177836431.47921,"amplitude":0.011673,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788998400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.674533,"peRate":32.802177,"turnoverRate":0.005453,"increases":49,"decrements":142,"flats":3,"marketCap":3707020015272.625,"floatMarketCap":3544092868972.125},"requestUrl":"/m/hq/s/BK4007/wiki","defaultTab":"wiki","newsList":[{"id":"2666530577","title":"InMed FY26 Net Loss Widens to Us$12.9 Million; Discontinued-Ops Sales Drop 36% to Us$3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530577","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530577?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:31","pubTimestamp":1788985898,"startTime":"0","endTime":"0","summary":"InMed FY26 net loss widens to US$12.9 million; discontinued-ops sales drop 36% to US$3.2 millionInMed Pharmaceuticals posted a net loss attributable to common shareholders of USD 12.99 million, wideni","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL60xxjp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530598","title":"Phibro Animal Health to Present at Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530598","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530598?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:30","pubTimestamp":1788985841,"startTime":"0","endTime":"0","summary":"Phibro Animal Health to Present at Morgan Stanley Global Healthcare ConferencePhibro Animal Health will present at the Morgan Stanley Annual Global Healthcare Conference on Sept. 15, 2026.Management i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL8C7ndm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LU2271345857.HKD","LU2357305700.SGD","LU0528227936.USD","LU0225283273.USD","LU1732800096.USD","LU2089284900.SGD","BK4588","LU0795875169.SGD","LU1548497426.USD","LU0053666078.USD","LU1074936037.SGD","IE00B775SV38.USD","IE00BZ1G4Q59.USD","BK4007","LU1989772923.USD","LU2133065610.SGD","LU1988902786.USD","LU1732799900.SGD","LU1244550494.USD","LU0234570918.USD","LU0106261372.USD","LU0158827948.USD","LU1791710582.SGD","BK4516","LU0795875086.SGD","LU2089283258.USD","LU0390134368.USD","LU2264538146.SGD","IAI","LU0557290698.USD","KBWB","BK4585","BK4127","LU0882574139.USD","LU1791710400.SGD","LU1720051017.SGD","LU2023251221.USD","PAHC","LU1244550221.USD","LU2111349929.HKD","LU1989772840.SGD","IE00B3S45H60.SGD","BK4534","LU0314104364.USD","LU2028103732.USD","LU0106831901.USD","LU0158827781.USD","LU0210528500.USD","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666700537","title":"Tarsus COO Neervannan Seshadri Sells 4,564 Shares Worth $387,940","url":"https://stock-news.laohu8.com/highlight/detail?id=2666700537","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666700537?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:13","pubTimestamp":1788984821,"startTime":"0","endTime":"0","summary":"Tarsus COO Neervannan Seshadri sells 4,564 shares worth $387,940Chief Operating Officer Neervannan Seshadri sold 4,564 Tarsus Pharmaceuticals common shares on Sept. 4, 2026 at USD 85.Directly held sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL3D86F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tarsus COO Neervannan Seshadri Sells 4,564 Shares Worth $387,940","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253723","title":"Rapport Therapeutics CEO Abraham Ceesay Sells $373,980 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253723","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253723?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:06","pubTimestamp":1788984374,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common sharesRapport Therapeutics CEO and director Abraham Ceesay sold 8,210 common shares on Sep. 8, 2026.Sales priced at USD 45.56 and USD 4","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL6DYrRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics CEO Abraham Ceesay Sells $373,980 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666766537","title":"Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666766537","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666766537?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:01","pubTimestamp":1788984060,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Sept.  09, 2026  -- Oruka Therapeutics, Inc.  , a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026.About Oruka TherapeuticsOruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. Investor Contact:Alan Lada-606-7911alan.lada@orukatx.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3359049/0/en/oruka-therapeutics-to-attend-the-2026-morgan-stanley-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU2133065610.SGD","XBI","LU1989772840.SGD","IAI","LU1668664300.SGD","LU0320765646.SGD","IE00B3S45H60.SGD","LU1732799900.SGD","LU0882574139.USD","HCSG","LU1791710582.SGD","LU0098860793.USD","LU2028103732.USD","LU1064131342.USD","LU0795875086.SGD","LU0128526141.USD","LU0795875169.SGD","IE00BZ1G4Q59.USD","BK4539","LU2089284900.SGD","LU0528227936.USD","BK4137","BK4007","BK4139","BK4588","KBWB","LU0557290698.USD","LU0158827781.USD","BK4504","LU0106261372.USD","LU1244550577.SGD","LU2487616109.SGD","BK4581","BK4534","BK4516","LU0006306889.USD","LU0912757837.SGD","LU2347655156.SGD","LU1548497426.USD","LU2089283258.USD","LENZ","LU2271345857.HKD","IE00BKVL7J92.USD","LU0971096721.USD","LU1162221912.USD","LABU","LU0390134368.USD","XLV","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666537638","title":"Obsidian Therapeutics participates in a conference call with William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2666537638","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666537638?lang=en_us&edition=fundamental","pubTime":"2026-09-10 03:25","pubTimestamp":1788981909,"startTime":"0","endTime":"0","summary":"William Blair holds a conference call with CEO Madan Jagasia, M.D on September 10 at 12 pm. Published first on TheFly – the ultimate source for rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/obsidian-therapeutics-participates-in-a-conference-call-with-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/obsidian-therapeutics-participates-in-a-conference-call-with-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858537","title":"Bayer Gets FDA Accelerated Approval for Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858537","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858537?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:55","pubTimestamp":1788980100,"startTime":"0","endTime":"0","summary":"Bayer received accelerated approval from the Food and Drug Administration for its treatment of non-small cell lung cancer.The FDA approved sevabertinib as a first-line treatment for patients with adva","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BAYRY","BK4007","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666012532","title":"Opus Genetics up over 32%, on Track for Largest Percent Increase Since February 2020","url":"https://stock-news.laohu8.com/highlight/detail?id=2666012532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666012532?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:46","pubTimestamp":1788979560,"startTime":"0","endTime":"0","summary":"Opus Genetics, Inc.  is currently at $5.74, up $1.40 or 32.14%--Would be highest close since April 17, 2026, when it closed at $5.75--On pace for largest percent increase since Feb. 11, 2020, when it rose 79.31%--Currently up five of the past six days--Up 58.43% month-to-date--Up 185.32% year-to-date--Down 99.94% from its all-time closing high of $10080.00 on Dec. 15, 2004--Up 331.2% from 52 weeks ago , when it closed at $1.33--Down 0.26% from its 52-week closing high of $5.75 on April 17, 2026--Up 331.2% from its 52-week closing low of $1.33 on Sept. 10, 2025--Traded as high as $7.07; highest intraday level since April 5, 2021, when it hit $7.28--Up 62.9% at today's intraday high; largest intraday percent increase since June 2, 2025, when it rose as much as 75.97%All data as of 2:44:02 PM ETSource: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666162532","title":"Opus Genetics Reach 52-Week High on Clinical Trial, FDA Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666162532","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666162532?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:08","pubTimestamp":1788977280,"startTime":"0","endTime":"0","summary":"Shares of Opus Genetics, which focuses on inherited retinal diseases, reached a 52-week high as it reported favorable drug study data and a successful meeting with the Food and Drug Administration.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007","PRGS","BK4097","LU2065732104.USD","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532138","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532138","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666532138?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:05","pubTimestamp":1788977158,"startTime":"0","endTime":"0","summary":"SUNation Energy  shares surged 60% after Suniva reported late Tuesday the close of an $835 million capital raise. The duo struck a reverse merger deal in June.Intraday trading volume catapulted to over 70.8 million from a daily average of about 2.5 million.InnovAge  swung to a profit in fiscal Q4 following a better-than-expected sales growth.Shares jumped 8%, with intraday trading volume rising to over 612,000 from a daily average of about 317,000.Opus Genetics  said Wednesday patients with BEST1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 clinical trial evaluating OPGx-BEST1.Wedbush Securities raised its price target for the stock to $13 from $10 while maintaining its outperform rating.Shares surged 25% as intraday trading volume soared to over 43.6 million from a daily average of roughly 1.1 million.Price: 3.85, Change: +1.48, Percent Change: +62.24","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MARS","IRD.AU","BK4007","DIPR","ROKT","ORBX","BK4089","BK4564","INNV","IRD","XTL","BK7129","BK4139","LU0054578231.USD","WARP","BK4196","SUNE","IRDM","BK4096","COWG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666329645","title":"Opus Genetics price target raised to $16 from $13 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2666329645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666329645?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:40","pubTimestamp":1788975649,"startTime":"0","endTime":"0","summary":"Chardan analyst Andreas Argyrides raised the firm’s price target on Opus Genetics (IRD) to $16 from $13 and keeps a Buy rating on the shares follow...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-raised-to-16-from-13-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-raised-to-16-from-13-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BNTX","BK4568","BK4535","BK4585","BK4551","IRD","BK4588","BK4548","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532336","title":"TwoStep Therapeutics Raises $62.5 Million in Series a Led by Insight Partners, Medical Excellence Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532336","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666532336?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:38","pubTimestamp":1788975520,"startTime":"0","endTime":"0","summary":"TwoStep Therapeutics raises $62.5 million in Series A led by Insight Partners, Medical Excellence CapitalTwoStep Therapeutics raised a USD 62.5 million oversubscribed Series A led by Insight Partners,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL44Fpct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LU1023059063.AUD","LU1057294990.SGD","SG9999002224.SGD","SG9999002232.USD","SG9999003800.SGD","LU0321505868.SGD","BK4581","BK4550","LU1066053197.SGD","LU0868494617.USD","LU1883839398.USD","BK4592","LU1894683264.USD","BK4533","LU0289739699.SGD","IE00BLSP4452.SGD","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","LU0321505439.SGD","SG9999013999.USD","BK4588","LU0234572021.USD","OZEM","LU1066051498.USD","BK4599","LU0985481810.HKD","BK4007","LU2596442595.SGD","BK4585","IE00BLSP4239.USD","BK4534","IE00B19Z3581.USD","SG9999001176.SGD","LU0306806265.USD","IE00B3T34201.USD","BK4568","LU0456855351.SGD","LU0170899867.USD","LU0306807586.USD","SGXZ57979304.SGD","PFE","LU0058720904.USD","IE0002270589.USD","LU0225284248.USD","IE000M9KFDE8.USD","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666953424","title":"PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo","url":"https://stock-news.laohu8.com/highlight/detail?id=2666953424","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666953424?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:18","pubTimestamp":1788974333,"startTime":"0","endTime":"0","summary":"BRIEF-PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAlloSept 9 (Reuters)-PureTech Health PLCPRTC.L:PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS REPORTS POS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PRTC.UK","SPTX","BK5083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534453","title":"PureTech Health: Glyphallo 375 Mg Did not Impair Next-Morning Driving Performance on Day 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534453?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","PRTC.UK","BK4007","BK5083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534285","title":"PureTech Health: Glyphallo was Well-Tolerated, with no Serious Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534285?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PRTC.UK","BK5083","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666498534","title":"PureTech Health: to Submit Glyphallo Phase 1 Results to U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2666498534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666498534?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK5083","BK4007","PRTC.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534593","title":"Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534593","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534593?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:34","pubTimestamp":1788971698,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $10.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK4139","BK4007","BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534630","title":"Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534630?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:31","pubTimestamp":1788971502,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk’s new Phase 3 trial, “Efficacy and Safety of Once Daily Oral ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","NVOC","BK4532","LU1093756168.USD","THNR","BK4588","BK4585","NVOH","BK4599","IE00BKVL7J92.USD","PPH","BK4007","NVO","OZEM","LU0154236417.USD","IE00BZ1G4Q59.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534883","title":"Pharvaris Price Target Raised to $65.00/Share from $50.00 by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534883?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:16","pubTimestamp":1788970560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHVS/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531005","title":"Novartis AG Falls Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531005?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:15","pubTimestamp":1788970500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.1% to CHF111.66 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 1.8% to 13,804.70.Novartis AG closed CHF21.02 below its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 4,314,570, compared to the 50-day average trading volume of 2,451,167.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","MEDX","LU0320765489.SGD","BK4585","BK4007","BK4578","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0208291251.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4532","LU0211331839.USD","BK4588","PPH","IE00B4R5TH58.HKD","IE0009355771.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4007","nameEN":"BK4007"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmacy(BK4007) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmacy,BK4007,Pharmacy股票,Pharmacy股票老虎,Pharmacy股票老虎国际,Pharmacy行情,Pharmacy股票行情,Pharmacy股价,Pharmacy股市,Pharmacy股票价格,Pharmacy股票交易,Pharmacy股票购买,Pharmacy股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmacy(BK4007) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction